These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Oelze M; Daiber A; Brandes RP; Hortmann M; Wenzel P; Hink U; Schulz E; Mollnau H; von Sandersleben A; Kleschyov AL; Mülsch A; Li H; Förstermann U; Münzel T Hypertension; 2006 Oct; 48(4):677-84. PubMed ID: 16940222 [TBL] [Abstract][Full Text] [Related]
23. Nebivolol attenuates prooxidant and profibrotic mechanisms involving TGF-β and MMPs, and decreases vascular remodeling in renovascular hypertension. Ceron CS; Rizzi E; Guimarães DA; Martins-Oliveira A; Gerlach RF; Tanus-Santos JE Free Radic Biol Med; 2013 Dec; 65():47-56. PubMed ID: 23806385 [TBL] [Abstract][Full Text] [Related]
24. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Stas S; Whaley-Connell A; Habibi J; Appesh L; Hayden MR; Karuparthi PR; Qazi M; Morris EM; Cooper SA; Link CD; Stump C; Hay M; Ferrario C; Sowers JR Endocrinology; 2007 Aug; 148(8):3773-80. PubMed ID: 17494996 [TBL] [Abstract][Full Text] [Related]
25. Effects of Single and Combined Losartan and Tempol Treatments on Oxidative Stress, Kidney Structure and Function in Spontaneously Hypertensive Rats with Early Course of Proteinuric Nephropathy. Karanovic D; Grujic-Milanovic J; Miloradovic Z; Ivanov M; Jovovic D; Vajic UJ; Zivotic M; Markovic-Lipkovski J; Mihailovic-Stanojevic N PLoS One; 2016; 11(8):e0161706. PubMed ID: 27560781 [TBL] [Abstract][Full Text] [Related]
26. Nebivolol-induced vasodilation of renal afferent arterioles involves β3-adrenergic receptor and nitric oxide synthase activation. Feng MG; Prieto MC; Navar LG Am J Physiol Renal Physiol; 2012 Sep; 303(5):F775-82. PubMed ID: 22674024 [TBL] [Abstract][Full Text] [Related]
27. Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: reversal by angiotensin II type 1 receptor blockade. Xu ZG; Lanting L; Vaziri ND; Li Z; Sepassi L; Rodriguez-Iturbe B; Natarajan R Circulation; 2005 Apr; 111(15):1962-9. PubMed ID: 15837950 [TBL] [Abstract][Full Text] [Related]
29. Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury. Whaley-Connell A; DeMarco VG; Lastra G; Manrique C; Nistala R; Cooper SA; Westerly B; Hayden MR; Wiedmeyer C; Wei Y; Sowers JR Am J Nephrol; 2008; 28(1):67-75. PubMed ID: 17914247 [TBL] [Abstract][Full Text] [Related]
30. Nebivolol ameliorated kidney damage in Zucker diabetic fatty rats by regulation of oxidative stress/NO pathway: Comparison with captopril. Wang Y; An W; Zhang F; Niu M; Liu Y; Shi R Clin Exp Pharmacol Physiol; 2018 Nov; 45(11):1135-1148. PubMed ID: 29935093 [TBL] [Abstract][Full Text] [Related]
32. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Gupta S; Wright HM Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089 [TBL] [Abstract][Full Text] [Related]
33. Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathway. Whaley-Connell AT; Habibi J; Nistala R; DeMarco VG; Pulakat L; Hayden MR; Joginpally T; Ferrario CM; Parrish AR; Sowers JR Am J Nephrol; 2012; 35(1):90-100. PubMed ID: 22205374 [TBL] [Abstract][Full Text] [Related]
34. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Mollnau H; Schulz E; Daiber A; Baldus S; Oelze M; August M; Wendt M; Walter U; Geiger C; Agrawal R; Kleschyov AL; Meinertz T; Münzel T Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):615-21. PubMed ID: 12692005 [TBL] [Abstract][Full Text] [Related]
35. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. Kamp O; Metra M; Bugatti S; Bettari L; Dei Cas A; Petrini N; Dei Cas L Drugs; 2010; 70(1):41-56. PubMed ID: 20030424 [TBL] [Abstract][Full Text] [Related]
36. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Whaley-Connell AT; Chowdhury NA; Hayden MR; Stump CS; Habibi J; Wiedmeyer CE; Gallagher PE; Tallant EA; Cooper SA; Link CD; Ferrario C; Sowers JR Am J Physiol Renal Physiol; 2006 Dec; 291(6):F1308-14. PubMed ID: 16788142 [TBL] [Abstract][Full Text] [Related]
37. Effect of nebivolol on cardiovascular changes associated with a rat model of insulin-resistance. Renna N; Risler N; Cruzado M; Gonzalez S; Lama C; Miatello RM Cell Mol Biol (Noisy-le-grand); 2005 Nov; 51(6):531-7. PubMed ID: 16309577 [TBL] [Abstract][Full Text] [Related]
38. The effect of progressive glomerular disease on megalin-mediated endocytosis in the kidney. Vinge L; Lees GE; Nielsen R; Kashtan CE; Bahr A; Christensen EI Nephrol Dial Transplant; 2010 Aug; 25(8):2458-67. PubMed ID: 20200006 [TBL] [Abstract][Full Text] [Related]
39. Proximal tubule angiotensin AT2 receptors mediate an anti-inflammatory response via interleukin-10: role in renoprotection in obese rats. Dhande I; Ali Q; Hussain T Hypertension; 2013 Jun; 61(6):1218-26. PubMed ID: 23547236 [TBL] [Abstract][Full Text] [Related]
40. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. Cominacini L; Fratta Pasini A; Garbin U; Nava C; Davoli A; Criscuoli M; Crea A; Sawamura T; Lo Cascio V J Am Coll Cardiol; 2003 Nov; 42(10):1838-44. PubMed ID: 14642697 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]